Skip to main content

ChEMBL 21 Released

By

We are pleased to announce the release of ChEMBL_21. This version of the database was prepared on 1st February 2016 and contains:

• 1,929,473 compound records
• 1,592,191 compounds (of which 1,583,897 have mol files)
• 13,968,617 activities
• 1,212,831 assays
• 11,019 targets
• 62,502 source documents

Data can be downloaded from the ChEMBL ftpsite or viewed via the ChEMBL interface. Please see ChEMBL_21 release notes for full details of all changes in this release.


CHANGES SINCE THE LAST RELEASE

In addition to the regular updates to the Scientific Literature, PubChem, FDA Orange Book and USP Dictionary of USAN and INN Investigational Drug Names this release of ChEMBL also includes the following new data:

* Data Depositions

Eight new deposited data sets have been included in ChEMBL_21. These include HepG2 cell viability data for the Gates Library Compound Collection from the University of Dundee, three depositions from groups screening the MMV Malaria Box (from TropIQ, Netherlands; Mahidol University, Thailand and Keele University, United Kingdom), anti-protozoal screening data from DNDi, anti-kinetoplastid screening data from GSK Tres Cantos, Leishmania screening data from St. Jude Children’s Hospital and carnitine palmitoyltransferase modulator screening data from Roche.

* Clinical Candidates

We have added >900 additional compounds in clinical development (phase I-III) to ChEMBL. These candidates mainly cover kinase, GPCR and nuclear hormone receptor targets. For each of these new candidates, we have curated likely efficacy targets (from a variety of sources such as scientific literature and pharmaceutical company pipeline documents) and added this information to the database. We have also updated the highest known development phase for compounds already in ChEMBL (such as monoclonal antibodies and compounds with USAN applications). We will continue to add further clinical candidate and target information in future releases (including targets for the existing monoclonal antibody candidates, and candidates for ion channel targets). Mechanism of action information for clinical candidates has been added to the 'Browse Drug Targets' tab on the ChEMBL interface, as well as the Compound and Target Report Cards:


* Drug Indications

We have identified indications for FDA approved drugs from a number of sources including Prescribing Information, ClinicalTrials.gov and the WHO ATC classification and mapped these to both MeSH disease identifiers and Experimental Factor Ontology disease identifiers. We will add further indications for compounds in clinical development in future ChEMBL releases. Drug indications can be viewed on Compound Report Cards and also on the 'Browse Drug Indications' tab:



* Drug Metabolism and Pharmacokinetic data

We have extracted drug metabolism and pharmacokinetic (PK) data from a number of data sources:
- Curated Drug Metabolism Pathways from a variety of literature/reference sources
- FDA Drug Approval Packages
- Drug Metabolism and Disposition Journal

Experimental assay data from these sources can be viewed via the Compound and Assay Report Cards and Bioactivity Summary views as usual. Further interface enhancements will be included in the near future to allow browsing of drug metabolism pathway data.

* GO Drug Target Slim:

We have created a Gene Ontology slim (GO slim) containing a subset of Gene Ontology terms that are well represented in protein targets from the ChEMBL database (see http://geneontology.org/page/go-slim-and-subset-guide and http://www.geneontology.org/ontology/subsets/goslim_chembl.obo). Targets can now be browsed by GO slim terms on the interface:



* HELM Notation

HELM Notations for monoclonal antibodies have been generated by Stefan Klostermann and team at Roche Diagnostics, and added to the database. In addition, HELM Notations have been generated for ~1100 new peptides that have been added to the ChEMBL_21 release.

* Improved Organism Classification

The organism classification has been enhanced for plant, insect and fungal targets to facilitate retrieval of crop protection data from the database. 


* RDF Update

ChEMBL 21 RDF files have been updated and can be downloaded from the ChEMBL-RDF ftpsite. The EBI-RDF Platform will be updated with the ChEMBL 21 RDF shortly.


We recommend you review the ChEMBL_21 release notes for a comprehensive overview of all updates and changes in ChEMBL 21, including schema changes, and as always, we greatly appreciate the reporting of any omissions or errors.

Keep an eye on the ChEMBL twitter and blog accounts for news and updates.

The ChEMBL Team






Comments

Unknown said…
This comment has been removed by the author.
4 March 2016 at 16:54
Post a Comment

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

By Eloy
    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by
Post a Comment
Read more

Improved querying for SureChEMBL

By
    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never
Post a Comment
Read more

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

By
In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen
Post a Comment
Read more

ChEMBL 34 is out!

By
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.
Post a Comment
Read more

A python client for accessing ChEMBL web services

By
Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d
1 comment
Read more